• In late June 2026, Alumis Inc. (NasdaqGS: ALMS) was removed from several Russell value and microcap indices while being added to multiple Russell growth benchmarks, including the Russell 2000 Growth, 2500 Growth, and 3000 Growth indices.
• This reshuffling signals a formal shift in how index providers classify Alumis, from value and microcap exposure toward inclusion in growth-focused small- and mid-cap benchmarks.
• We’ll now examine how Alumis’s reclassification into Russell growth benchmarks shapes its investment narrative, particularly around index-driven ownership and liquidity.

This technology could replace computers: discover 30 stocks that are working to make quantum computing a reality.

What Is Alumis' Investment Narrative?

For anyone considering Alumis, the core belief is that its TYK2 franchise can eventually justify today’s loss-making profile and ongoing dilution. The recent shift into Russell growth benchmarks lines up with that story, but it does not change the near-term reality that the key catalysts remain clinical and regulatory: the psoriasis NDA filing planned for the second half of 2026 and LUMUS SLE data in the third quarter. Index reclassification may influence which funds own the stock and tweak liquidity, especially after a very large 1‑year share price move, but it does not remove fundamental risks such as continued heavy cash burn, the auditor’s going concern flag, or potential equity raises under the US$300 million ATM. If anything, the growth label simply puts those risks under a brighter spotlight.

However, the going concern warning is something investors should be very clear on. Our expertly prepared valuation report on Alumis implies its share price may be too high.

Exploring Other Perspectives

Three Simply Wall St Community fair value views span roughly US$2 to US$40, showing how far apart private investors can be. Set against Alumis’ cash burn and ongoing losses, that spread underlines why it helps to weigh several viewpoints before deciding how the growth story might fit into a portfolio.

Explore 3 other fair value estimates on Alumis - why the stock might be worth as much as 52% more than the current price!

Decide For Yourself

Disagree with this assessment? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Alumis research is our analysis highlighting 1 key reward and 2 important warning signs that could impact your investment decision.
• Our free Alumis research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Alumis' overall financial health at a glance.

Looking For Alternative Opportunities?

Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

• AI is about to change healthcare. These 40 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Outshine the giants: these 15 early-stage AI stocks could fund your retirement.
• Capitalize on the AI infrastructure supercycle with our selection of the 51 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.